What is Achieve Life Sciences Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Achieve Life Sciences's interest expense for the
three
months ended in Mar. 2024 was $ -0.81 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.09 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Achieve Life Sciences's Operating Income for the
three
months ended in Mar. 2024 was $ -5.98 Mil. Achieve Life Sciences's Interest Expense for the
three
months ended in Mar. 2024 was $ -0.81 Mil.
Achieve Life Sciences did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Achieve Life Sciences Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.09 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Achieve Life Sciences (NAS:ACHV) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Achieve Life Sciences's Interest Expense for the
three
months ended in Mar. 2024 was $-0.81 Mil. Its
Operating Income
for the
three
months ended in Mar. 2024 was $-5.98 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2024 was $0.00 Mil.
Achieve Life Sciences's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
| Achieve Life Sciences did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Achieve Life Sciences (Achieve Life Sciences) Business Description
Traded in Other Exchanges
Address
22722 29th Dr. SE, Suite 1000, Bothell, WA, USA, 98021
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for nicotine addiction.
Executives
| John Bencich |
officer: CFO and PFO |
2401 FOURTH AVENUE, SUITE 1050, SEATTLE WA 98121 |
| Stuart Duty |
director |
22722 29TH DR SE, SUITE 100, BOTHELL WA 98021 |
| Thomas Sellig |
director |
22722 29TH DR SE, SUITE 100, BOTHELL WA 98021 |
| Thomas Braxton King |
director |
91 JAMES AVENUE, ATHERTON CA 94027 |
| Dialectic Life Sciences Spv Llc |
10 percent owner |
C/O DIALECTIC LS MANAGER LLC, 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853 |
| Dialectic Ls Manager Llc |
10 percent owner |
119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853 |
| John Fichthorn |
10 percent owner |
C/O DIALECTIC CAPITAL MANAGEMENT, LLC, 17 STATE STREET, SUITE 3930, NEW YORK NY 10004 |
| Dialectic Capital Management, Lp |
10 percent owner |
119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853 |
| Dialectic Partners, Llc |
10 percent owner |
2ND FLOOR 119 ROWAYTON AVE, NORWALK CT 06853 |
| Vaughn B Himes |
director |
C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021 |
| Financial Group Svb |
10 percent owner |
2270 SAND HILL ROAD, MENLO PARK CA 94025 |
| Svb Innovation Credit Partners Viii, Llc |
10 percent owner |
2770 SAND HILL ROAD, MENLO CITY CA 94025 |
| Svb Innovation Credit Fund Viii, L.p. |
10 percent owner |
C/O SVB INNOVATION CREDIT PARTNERS VIII, 2770 SAND HILL ROAD, MENLO PARK CA 94025 |
| Innovation Credit Fund Viii-a, L.p. |
10 percent owner |
2770 SAND HILL ROAD, MENLO PARK CA 94025 |
| Svb Innovation Credit Partners Viii-a, Llc |
10 percent owner |
2770 SAND HILL ROAD, MENLO CITY CA 94025 |
Achieve Life Sciences (Achieve Life Sciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ACHV has been successfully added to your 